LL-37ImmuneSafety Rating 6/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors · per 5mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| Ascension PeptidesBest $/mgCOA ✓ · 3P | $55.00 | $5.50 | Apr 16, 2026 | Buy → |
| PeptiraCOA ✓ · 3P | $39.00 | $7.80 | May 14, 2026 | Buy → |
| Pantheon PeptidesCOA ✓ · 3P | $63.50 | $12.70 | Apr 23, 2026 | Buy → |
| Modern AminosCOA ✓ · 3P | $64.00 | $12.80 | May 14, 2026 | Buy → |
| Swiss ChemsCOA ✓ · 3P | $71.99 | $14.40 | Apr 17, 2026 | Buy → $25 off $100+·auto |
Overview
About LL-37
Mechanism of action
Endogenous human cathelicidin antimicrobial peptide; disrupts bacterial membranes; stimulates wound healing; modulates innate immune response; promotes angiogenesis; anti-biofilm activity.
Safety profile
Injection site reactions; skin irritation; potential inflammatory response at high doses. Long-term data limited. · Endogenous cathelicidin; naturally occurring; potential pro-inflammatory at very high doses only
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops LL-37 below your target.
Safety & Interactions
Contraindications & Drug Interactions
Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.
High doses may be pro-inflammatory (opposite of intended effect). Dose-dependent biology.
Related pages
More on LL-37
Research
Studies & key findings
- LL-37 is the sole human cathelicidin, a 37-amino-acid cationic amphipathic peptide cleaved from the precursor hCAP18; it exerts broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, fungi, and viruses via membrane permeabilization, pore formation, and intracellular target disruption — in addition to neutralizing bacterial LPS.
- In wound healing, LL-37 is strongly expressed at acute wound edges (peak at 48 h) and markedly absent in chronic ulcer epithelium; antibody-mediated blockade of LL-37 in ex vivo human skin significantly inhibits re-epithelialization, confirming a causal role via EGFR transactivation that activates STAT3 and Snail/Slug transcription factors to drive keratinocyte migration.